A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

Completed · Phase 4

Conditions studied: Graft Rejection, Kidney Transplantation

In brief

A study to compare the conversion to Prograf® (tacrolimus) to the continuation of cyclosporine in patients at risk for chronic renal allograft failure

Key facts

Study ID

NCT00510913

Run by

Astellas Pharma Inc

People needed

450

Starts

1999-02-01

Expected to finish

2000-09-01

Last updated by the study team

2007-08-02

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient has been on cyclosporine-based immunosuppression regimen since the transplant
• Patient has at least one pre-defined risk factor for chronic allograft failure

You may not qualify if…

• Patient is dialysis dependent
• Patient is recipient of a solid organ transplant other than the kidney

Where it is running

• Study site — Los Angeles, California, United States
• Study site — San Diego, California, United States
• Study site — San Francisco, California, United States
• Study site — Denver, Colorado, United States
• Study site — New Haven, Connecticut, United States
• Study site — Augusta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Lexington, Kentucky, United States
• Study site — Baltimore, Maryland, United States
• Study site — Boston, Massachusetts, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — Albany, New York, United States
• Study site — New York, New York, United States
• Study site — Portland, Oregon, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Nashville, Tennessee, United States
• Study site — Salt Lake City, Utah, United States
• Study site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.